Drug delivery to the brain is greatly hampered by the presence of the blood-brain barrier (BBB) which tightly regulates the passage of molecules from blood to brain and vice versa. Nanocarriers, in which drugs can be encapsulated, can move across the blood-brain barrier (BBB) via the process of transcytosis, thus showing promise to improve drug delivery to the brain. Here, we demonstrate the use of natural nanovesicles, that is, exosomes, derived from C17.2 neural stem cells (NSCs) to efficiently carry a protein cargo across an in vitro BBB model consisting of human brain microvascular endothelial cells. We show that the exosomes are primarily taken up in brain endothelial cells via endocytosis, while heparan sulfate proteoglycans (HSPGs) a...
Efficient drug delivery across biological barriers is a central problem in pharmaceutical treatment ...
The possibility to treat central nervous system (CNS) disorders is strongly limited by the poor acce...
Challenges in drug development of neurological diseases remain mainly ascribed to the blood-brain ba...
Drug delivery to the brain is greatly hampered by the presence of the blood-brain barrier (BBB) whic...
Recent work has stimulated interest in the use of exosomes as nanocarriers for delivery of small dru...
Extracellular vesicles (EVs) are nanoparticles released from cells, which play an important role in ...
The blood-brain barrier prevents the entry of many therapeutic agents into the brain. Various nanoca...
The blood-brain barrier acts as a physical barrier that prevents free entry of blood-derived substan...
Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to in...
Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to in...
Abstract Nowadays, a large population around the world, especially the elderly, suffers from neurolo...
Drug delivery to the central nervous system (CNS) is limited due to the presence of the blood–brain ...
Brain cancer treatments have long been restricted by the blood-brain barrier (BBB). Semi-permeable i...
Nanosized drug delivery systems targeting transporters of the blood-brain barrier (BBB) are promisin...
The blood-brain barrier, as a physical, active transport and metabolic barrier represents the main o...
Efficient drug delivery across biological barriers is a central problem in pharmaceutical treatment ...
The possibility to treat central nervous system (CNS) disorders is strongly limited by the poor acce...
Challenges in drug development of neurological diseases remain mainly ascribed to the blood-brain ba...
Drug delivery to the brain is greatly hampered by the presence of the blood-brain barrier (BBB) whic...
Recent work has stimulated interest in the use of exosomes as nanocarriers for delivery of small dru...
Extracellular vesicles (EVs) are nanoparticles released from cells, which play an important role in ...
The blood-brain barrier prevents the entry of many therapeutic agents into the brain. Various nanoca...
The blood-brain barrier acts as a physical barrier that prevents free entry of blood-derived substan...
Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to in...
Nanoparticles targeting transporters of the blood-brain barrier (BBB) are promising candidates to in...
Abstract Nowadays, a large population around the world, especially the elderly, suffers from neurolo...
Drug delivery to the central nervous system (CNS) is limited due to the presence of the blood–brain ...
Brain cancer treatments have long been restricted by the blood-brain barrier (BBB). Semi-permeable i...
Nanosized drug delivery systems targeting transporters of the blood-brain barrier (BBB) are promisin...
The blood-brain barrier, as a physical, active transport and metabolic barrier represents the main o...
Efficient drug delivery across biological barriers is a central problem in pharmaceutical treatment ...
The possibility to treat central nervous system (CNS) disorders is strongly limited by the poor acce...
Challenges in drug development of neurological diseases remain mainly ascribed to the blood-brain ba...